Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

USA - NASDAQ:NMTC - US64130M2098 - Common Stock

0.7185 USD
-0.01 (-1.82%)
Last: 11/6/2025, 8:00:02 PM
0.7185 USD
0 (0%)
After Hours: 11/6/2025, 8:00:02 PM
Fundamental Rating

3

NMTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While NMTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NMTC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
In the past 5 years NMTC always reported negative net income.
NMTC had a negative operating cash flow in each of the past 5 years.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

NMTC has a Return On Assets of -49.33%. This is in the lower half of the industry: NMTC underperforms 66.67% of its industry peers.
NMTC's Return On Equity of -65.26% is in line compared to the rest of the industry. NMTC outperforms 44.44% of its industry peers.
Industry RankSector Rank
ROA -49.33%
ROE -65.26%
ROIC N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

NMTC has a better Gross Margin (70.14%) than 79.89% of its industry peers.
NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NMTC has been increased compared to 1 year ago.
Compared to 5 years ago, NMTC has more shares outstanding
NMTC has a worse debt/assets ratio than last year.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NMTC has an Altman-Z score of -1.67. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.67, NMTC perfoms like the industry average, outperforming 40.21% of the companies in the same industry.
NMTC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.13, NMTC is doing good in the industry, outperforming 61.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -1.67
ROIC/WACCN/A
WACC8.67%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NMTC has a Current Ratio of 7.13. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a Current ratio of 7.13. This is amongst the best in the industry. NMTC outperforms 86.24% of its industry peers.
A Quick Ratio of 5.80 indicates that NMTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.80, NMTC belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 5.8
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.67% over the past year.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 142.96%.
Measured over the past years, NMTC shows a very strong growth in Revenue. The Revenue has been growing by 143.22% on average per year.
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%

3.2 Future

NMTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.96% yearly.
Based on estimates for the next years, NMTC will show a very strong growth in Revenue. The Revenue will grow by 34.68% on average per year.
EPS Next Y72.62%
EPS Next 2Y28.64%
EPS Next 3Y19.96%
EPS Next 5YN/A
Revenue Next Year27.11%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1

4.3 Compensation for Growth

NMTC's earnings are expected to grow with 19.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.64%
EPS Next 3Y19.96%

More info and screens

0

5. Dividend

5.1 Amount

NMTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (11/6/2025, 8:00:02 PM)

After market: 0.7185 0 (0%)

0.7185

-0.01 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)12-15 2025-12-15/amc
Inst Owners33.63%
Inst Owner Change0.02%
Ins Owners4.18%
Ins Owner Change-1.14%
Market Cap35.92M
Revenue(TTM)9.63M
Net Income(TTM)-5.34M
Analysts85
Price Target2.27 (215.94%)
Short Float %0.12%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)23.75%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)47.24%
Min EPS beat(4)-34.8%
Max EPS beat(4)158.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.92%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)-8.62%
Revenue beat(4)1
Avg Revenue beat(4)-21.92%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)2
Avg Revenue beat(8)-19.9%
Revenue beat(12)4
Avg Revenue beat(12)-5.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.54%
Revenue NQ rev (1m)17.49%
Revenue NQ rev (3m)10.73%
Revenue NY rev (1m)4.31%
Revenue NY rev (3m)2.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.73
P/FCF N/A
P/OCF N/A
P/B 4.39
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.19
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.33%
ROE -65.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.14%
FCFM N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.13%
Cap/Sales 1.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.13
Quick Ratio 5.8
Altman-Z -1.67
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
EPS Next Y72.62%
EPS Next 2Y28.64%
EPS Next 3Y19.96%
EPS Next 5YN/A
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
Revenue Next Year27.11%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.54%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ

What is the fundamental rating for NMTC stock?

ChartMill assigns a fundamental rating of 3 / 10 to NMTC.


What is the valuation status for NMTC stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROONE MEDICAL TECHNOLOGIE (NMTC). This can be considered as Overvalued.


What is the profitability of NMTC stock?

NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a profitability rating of 1 / 10.


What is the expected EPS growth for NEUROONE MEDICAL TECHNOLOGIE (NMTC) stock?

The Earnings per Share (EPS) of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to grow by 72.62% in the next year.